Molecular analyses of leukemia patients suggest strategies for better ...( The cure rate for pediatric acute lymph...),Health

The cure rate for pediatric acute lymphoblastic leukemia (ALL) might continue to rise with improved use of conventional therapies. But even more effective and less toxic therapies based on genetic and pharmacogenetic studies might one day push the success rate close to 100 percent, according to an article published by investigators at St. Jude Children's Research Hospital in the April 8 issue of the New England Journal of Medicine.

The St. Jude researchers base their prediction on their review of the current and evolving state of ALL diagnosis and treatment. ALL is a cancer in which an excess number of immature and non-functional white blood cells overwhelm the body's ability to make normal blood cells in the bone marrow. It is the most common type of cancer in children, with about 3,000 new cases each year in the United States alone. The survival has rate increased from 4 percent--when St. Jude opened in 1962--to 80 percent today, following the development of protocol-based treatment at St. Jude that combined different anti-ALL drugs and revolutionized the treatment of ALL.

"The substantial progress in ALL treatment being made today at St. Jude and other institutions reflects not only a more effective use of combining traditional anti-leukemic drugs, but also significant breakthroughs in genetic studies of ALL patients," said Ching-Hon Pui, M.D., director of the St. Jude Leukemia Lymphoma division and the F.M. Kirby Clinical Research Professor for the American Cancer Society.

A key advantage to the genetic approach to ALL treatment is the increasing ability of physicians to identify which gene mutations are linked to increased or decreased responsiveness to anti-leukemic drugs. This information is helping researchers to identify children who have particularly drug-resistant forms of ALL, as well as patients who are more susceptible to the toxicities of specific treatments. The new approach is also guiding development of new drugs that target specif
'"/>

Contact: Bonnie Cameron
bonnie.cameron@stjude.org
901-495-4815
St. Jude Children's Research Hospital
7-Apr-2004

Page: 1 2 3
Related medicine news :

1. Molecular test predicts risk of breast cancer recurrence and who will benefit from chemotherapy
2. Jefferson and Molecular Targeting Technologies, Inc. scientists create vaccine for wildlife rabies
3. Molecular tailoring of chemotherapy with novel imaging techniques
4. Molecular clock genes influence metabolism of sugar and dietary fats
5. Data announced at ISHLT: Molecular testing proves effective in monitoring heart transplant rejection
6. Molecular test proves to be effective in measuring remission and relapse after cancer treatment
7. Molecular tag pinpoints which breast cancer tumors are most likely to spread
8. Molecular mechanism underlaying anthrax infection described by UCSD School Of Medicine researchers
9. Molecularly targeted drug slows tumor growth in patients
10. Molecular self-assembly techniques used to coat biomedical substrates
11. Molecular nanogenerator developed that can target cancer cells and destroy them